Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01081912
Other study ID # ZX002-0801
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 2010
Est. completion date October 2011

Study information

Verified date March 2014
Source UCB Pharma
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain.


Description:

A randomized Phase 3, placebo-controlled multi-center study to evaluate the safety, efficacy and tolerability of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain. Subjects will go through an open-label conversion and titration phase followed by a randomized double-blind treatment phase of Hydrocodone (HC)-Controlled-Release (CR) vs. Placebo. The trial will consist of a Screening Phase (up to 14 days), an open-label Conversion and Titration Phase (up to 6 weeks), a 12-week placebo-controlled Treatment Phase, and a 2-week Follow-Up Phone Call


Recruitment information / eligibility

Status Completed
Enrollment 510
Est. completion date October 2011
Est. primary completion date October 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Subjects must have a clinical diagnosis of moderate to severe chronic lower back pain (CLBP) - Subjects must be classified as non-neuropathic, neuropathic, or symptomatic for more than 6 months after lower back pain (LBP) surgery - Subjects must in the Investigator's opinion qualify for around-the-clock opioid therapy for treatment of their chronic lower back pain (CLBP). - Subjects must have been taking opioids for at least 5 days/week for the past 4weeks - Subjects must have an average Clinic Pain Score of = 4 on the 11-point (0-10) numeric rating scale (NRS) as an average for the last 24 hours of Screening - Subjects, in the opinion of the Investigator, must be considered to be in generally good health other then CLBP at Screening - Female subjects of childbearing potential must have a negative urine pregnancy test at the Screening Visit, and must consent to use a medically-acceptable method of contraception throughout the entire study period. - Subjects must voluntarily provide written informed consent. Exclusion Criteria: - Any clinically significant condition that would, in the opinion of the Investigator, preclude study participation or interfere with the assessment of pain and other symptoms of CLBP or increase the risk of opioid-related adverse events - A medical condition that, in the opinion of the Investigator, would compromise the subject's ability to swallow, absorb, metabolize, or excrete the study drug - A surgical procedure for back pain within 6 months - A nerve or plexus block, including epidural steroid injections or facet blocks - A history of chemotherapy or confirmed malignancy within past 2 years - Any other chronic pain condition other than CLBP that, in the Investigator's opinion, would interfere with the assessment of LBP e.g. fibromyalgia, osteoarthritis, rheumatoid arthritis, migraine headaches requiring opioid treatment - Uncontrolled blood pressure, i.e., subject has a sitting systolic blood pressure >180 mmHg or <90 mmHg, and/or a sitting diastolic blood pressure >120 mmHg or <50 mmHg at Screening - A Body Mass Index (BMI) >45 kg/m2 - A Hospital Anxiety and Depression Scale (HADS) Index score of >12 in either depression or anxiety subscales or an established history of major depressive disorder that is poorly controlled with medication - A clinically significant abnormality in clinical chemistry, hematology or urinalysis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Placebo
Capsules, no active substance, shells identical to active comparator capsules
Hydrocodone bitartrate
dosage form: capsule Strengths 10mg, 20mg, 30mg, 40mg, 50mg

Locations

Country Name City State
United States Advanced Clinical Research Institute Anaheim California
United States Perimeter Institute for Clinical Research, Inc. Atlanta Georgia
United States Northwest Clinical Research Center Bellevue Washington
United States Center for Clinical Trials Biloxi Mississippi
United States South Jersey Medical Associates Blackwood New Jersey
United States River Birch Research Alliance, LLC Blue Ridge Georgia
United States Five Towns Neuroscience Research Cedarhurst New York
United States Suburban Clinical Research Chicago Illinois
United States IVA Research Cincinnati Ohio
United States Clinical Research of West Florida, Inc. Clearwater Florida
United States Clinicos, LLC Colorado Springs Colorado
United States New England Center for Clinical Research Cranston Rhode Island
United States InSite Clinical Research DeSoto Texas
United States Brandywine Clinical Research Downingtown Pennsylvania
United States Destiny Clinical Research, LLC Evansville Indiana
United States NECCR Internal Medicine & Cardiology Associates, LLC Fall River Massachusetts
United States Feasterville Family Health Care Center Feasterville Pennsylvania
United States Prestige Clinical Research Franklin Ohio
United States Neuro-Pain Medical Center, Inc. Fresno California
United States Clinical Trial Network Houston Texas
United States Florida Institute of Medical Research Jacksonville Florida
United States Clopton Clinic Jonesboro Arkansas
United States Research West, LLC Kalispell Montana
United States Pacific Coast Pain Management Center Laguna Hills California
United States Office of Danka Michaels, MD Las Vegas Nevada
United States International Clinical Research Institute Leawood Kansas
United States Interwest Rehabilitation, LLC Littleton Colorado
United States Georgia Institute for Clinical Research, LLC Marietta Georgia
United States Clinical Trials Management Metairie Louisiana
United States Integrity Clinical Research, LLC Milan Tennessee
United States Best Clinical Trials, LLC New Orleans Louisiana
United States Advanced Research Institute Ogden Utah
United States Neuropsychiatric Research Center Oklahoma City Oklahoma
United States Peninsula Research, Inc. Ormond Beach Florida
United States Arizona Research Center Phoenix Arizona
United States Gold Coast Research Plantation Florida
United States Clinical Trials Technology, Inc Prairie Village Kansas
United States Health Concepts Rapid City South Dakota
United States Hypothe Test, LLC Roanoke Virginia
United States Innovative Clinical Trials San Antonio Texas
United States Invisions Consultants, LLC San Antonio Texas
United States River Cities Clinical Research Center Shreveport Louisiana
United States Georgia Clinical Research Snellville Georgia
United States Clinical Trial Network Spring Texas
United States Stamford Therapeutics Consortium Stamford Connecticut
United States Clinical Research of West Florida, Inc. Tampa Florida
United States Cotton O'Neil Clinical Research Center Topeka Kansas
United States Integrated Clinical Trials Services, Inc. West Des Moines Iowa
United States Upstate Clinical Research Associates Williamsville New York
United States CRI Worldwide, LLC Willingboro New Jersey
United States Center for Clinical Research LLC Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Zogenix, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean Change in 24-hour Pain Intensity Ratings Scale (NRS). Change in average pain intensity as measured daily by Numeric Rating Scale (NRS) for Pain (0-10; where 0 = no pain, 10 = worst pain imaginable) comparing HC-ER with Placebo. Lower number equals better outcome. Baseline to Day 85 (Treatment Phase)
Secondary Mean Change of the Clinic NRS Pain Intensity The change in pain intensity as measured in the clinic by a 0-10 Numeric Rating Scale (NRS) Baseline to Day 85 visit
See also
  Status Clinical Trial Phase
Completed NCT01914666 - An Open Label Extension Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain Phase 3
Completed NCT01761617 - Yoga Dosing Study for Chronic Low Back Pain N/A
Completed NCT03338192 - Examining Racial and SocioEconomic Disparities (ERASED) in Chronic Low Back Pain Study
Completed NCT03106740 - Evaluating the Role of Neuroinflammation in Low Back Pain Phase 2
Completed NCT02960269 - Interprofessional Management of Chronic Back Pain in Rural and Remote Setting: Use of Telehealth vs. Secure Laptop-based Videoconferencing N/A
Completed NCT04203888 - Personalized Trial for Chronic Lower Back Pain N/A
Not yet recruiting NCT05704751 - EVOKE ECAP-Controlled Lead Placement and Programming in Chronic Pain Patients
Completed NCT06351774 - Project AdaPT: An Adaptive Physiotherapy Intervention Augmented With a Healthy Mind Training Program for People With Chronic Low Back Pain N/A
Completed NCT01855919 - A Study of Duloxetine (LY248686) in Participants With Chronic Low Back Pain Phase 3
Terminated NCT01865539 - Efficacy of Foot Orthotics in Veterans With Chronic Lower Back Pain N/A
Enrolling by invitation NCT05386212 - The Impact of an Instructional Web-based Healthcare App for Relieving Back Pain From Spinal Compression Fractures
Completed NCT03299192 - Tai Chi for Chronic Low Back Pain in Older Adults N/A
Completed NCT04468074 - Virtual Reality Treatment for Adults With Chronic Back Pain N/A
Completed NCT01343927 - Yoga vs. Physical Therapy vs. Education for Chronic Low Back Pain in Minority Populations N/A
Completed NCT01329861 - Internet-based Cognitive Behavioural Treatment for Chronic Back Pain N/A
Terminated NCT01125917 - Safety of BTDS in Subjects With Low Back Pain: A 52-Week Extension Phase of BUP3015 Phase 3
Enrolling by invitation NCT05413070 - Quality Improvement re: Choosing Wisely Back Pain Measures
Not yet recruiting NCT06401499 - The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination Phase 4
Recruiting NCT04893720 - The SPINUS II Study: Spinal Fusion for Multilevel SPECT/CT Positive Lumbar Degeneration
Recruiting NCT05953155 - YOga for Patients With Chronic BACK Pain and Poor PROgnosis N/A